The earnings call highlighted significant progress in the development and funding of CD388, along with strong financial positioning. However, there are challenges related to manufacturing scale-up and uncertainties in flu vaccination rates and study enrollment timing.
Company Guidance
During the Cidara Therapeutics Q3 2025 Conference Call, the company provided detailed guidance on its lead candidate, CD388, which has advanced into Phase III development. The trial commenced six months earlier than planned, evaluating the drug's safety and efficacy in high-risk populations for influenza, with plans to enroll 6,000 participants across 150 sites. The study is over 50% enrolled and aims to complete Northern Hemisphere enrollment by December. The FDA granted CD388 breakthrough therapy designation, enhancing its regulatory pathway with potential priority review. The company secured $339 million from BARDA for expanded manufacturing and clinical development. Cidara holds approximately $476 million in cash, ensuring the Phase III program is fully funded. An interim analysis in Q1 2026 may influence further enrollment in the Southern Hemisphere. The company plans a virtual R&D Day on December 15 to update on CD388’s progress and commercial opportunities.
Accelerated Phase III Development of CD388
CD388 has advanced into Phase III development six months earlier than planned, with expanded patient population and FDA breakthrough therapy designation.
BARDA Funding Secured
Cidara received up to $339 million from BARDA to support CD388 manufacturing and clinical development, with $58 million for initial activities.
Strong Financial Position
Cidara has approximately $476 million in cash, fully funding the Phase III program through completion.
Positive Phase IIb Results
CD388's Phase IIb study met its primary endpoint with 76.1% protective efficacy, supporting Phase III dose selection.
Cidara Therapeutics (CDTX) Earnings, Revenues Date & History
The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
CDTX Earnings-Related Price Changes
Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
Nov 06, 2025
$98.64
$104.39
+5.83%
Aug 07, 2025
$61.73
$62.00
+0.44%
May 08, 2025
$19.15
$18.63
-2.72%
Mar 06, 2025
$23.61
$23.66
+0.21%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Cidara Therapeutics (CDTX) report earnings?
Cidara Therapeutics (CDTX) is schdueled to report earning on Mar 11, 2026, TBA (Confirmed).
What is Cidara Therapeutics (CDTX) earnings time?
Cidara Therapeutics (CDTX) earnings time is at Mar 11, 2026, TBA (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.